Tokyo, June 12 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061070) titled 'A study to confirm the effect of food containing lactic acid bacteria intake on bowel movements' on June 12.
Study Type:
Interventional
Study Design:
Basic Design - Parallel
Randomization - Randomized
Blinding - Double blind -all involved are blinded
Control - Placebo
Primary Sponsor:
Institute - MEGMILK SNOW BRAND Co., Ltd.
Condition:
Condition - Healthy volunteer
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate the effects of continuous intake of food containing lactic acid bacteria for 4 weeks on defecation.
Basic objectives2 - Efficacy
Intervention:
Interventions/Control_1 - Intake of active food for 4 weeks
Interventions/Control_2 - Intake of placebo food for 4 weeks
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Male and Female
Key inclusion criteria - 1)Healthy males and females aged 20-64 years at the time of consent to participate in the study.
2)Individuals with 3 to 5 bowel movements per week during the run-in period.
3)Individuals who can visit the trial site on the scheduled visit dates, and who can collect and submit fecal samples within the specified period.
4)Individuals who understand the purpose and content of the study and provide online informed consent prior to participation.
Key exclusion criteria - 1)Individuals who regulary take medicines/foods that affect the intestinal environment.
2)Individuals with a history of serious liver, kidney, cardiovascular, gastrointestinal, pulmonary, hematological, or metabolic disease.
3)Individuals with chronic diseases and who regularly use medicines.
4)Individuals with a current or history of drug or alcohol dependence.
5)Individuals with a history of gastrointestinal disease or surgery that affects digestion, absorption, or defecation.
6)Individuals with food allergies related to the test food.
7)Individuals with extremely irregular dailyand eating habits (including late-night workers).
8)Individuals who cannot restrict the use of drugs/foods that affect the study after providing informed consent.
9)Individuals with excessive exercise, drinking and smoking habits.
10)Pregnant or lactating women, or women who may become pregnant during the study period.
11)Individuals who have taken antibiotics within 1 month prior to providing informed consent or who will take antibiotics during the study period.
12)Individuals who have participated in, are currently participating in, or plan to participate in any other clinical research within 1 month prior to providing informed consent or during the study period.
13)Individuals who plan to change their lifestyle drastically after providing informed consent and before the end of the study.
14)Individuals who plan to travel abroad after providing informed consent and before the end of the study.
15)Individuals who are judged to be unsuitable based on their responses to the background questionnaire.
16)Other individuals who are judged by the investigator to be unsuitable for the study.
Target Size - 90
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 02 Month 24 Day
Date of IRB - 2026 Year 03 Month 02 Day
Anticipated trial start date - 2026 Year 06 Month 12 Day
Last follow-up date - 2026 Year 07 Month 25 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069881
Disclaimer: Curated by HT Syndication.